Editor of Patient Care Online.
Non-Hormonal Therapy for Menopausal VMS: How Does Elinzanetant Differ from HRT?
JoAnn Pinkerton, MD, national lead for the OASIS clinical trial program evaluating elinzanetant for menopausal VMS, discusses how non-hormonal therapy differs from HRT.
Novel Oral Antiobesity Drug Reduces Body Weight by up to 13%: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Approves First Self-Administered Flu Vaccine: Daily Dose
Menopausal Hormone Therapy Use Declined in Past 2 Decades among Women Regardless of Age, Race/Ethnicity
Use of menopausal hormone therapy decreased from nearly 27% to 5% among postmenopausal women between 1999 and 2020, according to new research.
Better CV Health in Early Pregnancy Offsets High Genetic Risk: Daily Dose
7 Drugs Approved for Primary Care: Q3 2024
Updated mRNA COVID-19 vaccines, the first orally disintegrating tablet approved for pregnancy prevention, and 5 more.
Atrial Fibrillation More Prevalent in US Than Previously Estimated: Daily Dose
Roflumilast Cream 0.15% Leads to Consistent Improvements in Atopic Dermatitis Across Diverse Skin Types
Roflumilast cream 0.15% was associated with consistent and meaningful improvements in AD clearance and itch reduction, according to new data.
Over Half of US Adults with Uncontrolled HTN Unaware of Their Condition: Daily Dose
Elinzanetant for Menopausal VMS: OASIS Lead Investigator Discusses Results, Side Effects, Next Steps
JoAnn Pinkerton, MD, details the positive findings from the OASIS 1, 2, and 3 studies of elinzanetant and highlights next steps in research.
FDA Approves Lebrikizumab-lbkz for Moderate to Severe AD: Daily Dose
High Percentage of Patients Seek Mental Health Care from PCPs, According to New Large Analysis
One in 9 primary care encounters involved a mental health condition, according to an analysis of over 350 million primary care visits.
September Issue of Patient Care Online Supplement is Now Live
Find details on advances in the management of type 1 diabetes, utilization of CGM in primary care settings, and optimizing T2D management in older persons.
RSV Vaccine Effective Against Hospitalization in Older Adults: Daily Dose
First Self-Administered Flu Vaccine Approved by US FDA
FluMist is the first influenza vaccine that does not have to be given by a health care professional.
ACIP Highlights Evidence Supporting Recommendation for PCV21 Vaccine for Adults
New report includes data on the safety and immunogenicity of the recently-approved PCV21 vaccine.
Tralokinumab for Treatment of AD in Special Populations: Daily Dose
Long-Term Safety of Roflumilast in Adults with COPD: Daily Dose
Novel Oral Antiobesity Drug Shown to Reduce Body Weight by up to 13% in First-In-Human Study
EASD 2024: Amycretin was also found to be safe and well tolerated in adults with obesity and without diabetes.
Recent Recreational Drug Use Ups Risk of Repeat Serious CV Event: Daily Dose
Good Cardiovascular Health Early on May Offset Genetic Risk of Hypertensive Disorders of Pregnancy
New data shows that favorable CV health in the first trimester is associated with a 35% to 62% lower risk of HDP regardless of level of genetic risk.
Corticosteroid Phobia among Individuals with Chronic Hand Eczema: Daily Dose
Mental Health Among Adolescents With Obesity: Daily Dose
Best States for Health Care in the US: 2024
Which state retains the most medical residents? Or has the lowest cancer rate? Answers and more insights from a nationwide analysis, here.
Statin Plus Ezetimibe Outperforms High-Dose Statins in LDL-C Reduction: Daily Dose
Survodutide: Novel GCGR/GLP-1RA Shows Promise in Obesity, MASH Treatment
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
Healthy Lifestyle May Offset Brain Aging Accelerated by Diabetes: Daily Dose
Lebrikizumab Therapy Improved QoL, Mental Health Outcomes in Patients with Atopic Dermatitis
In a study of persons with moderate-to-severe atopic dermatitis, lebrikizumab monotherapy for 16 weeks resulted in improved quality of life and mental health.
FDA Expands Omnipod 5 AID System Label to Treat T2D: Daily Dose
Tralokinumab May be Beneficial for Atopic Dermatitis Treatment in Special Patient Populations
In a study of patients with atopic dermatitis, tralokinumab was effective and safe in elderly patients and those with severe comorbidities.
